insitro inc
United States
About insitro inc
21 articles about insitro inc
-
insitro Hires Chief Medical Officer to Advance Therapeutic Programs Toward the Clinic
1/8/2024
insitro, a machine learning-powered drug discovery and development company, today announced the appointment of S. Michael Rothenberg, M.D., Ph.D., as chief medical officer.
-
AI and machine learning could transform drug discovery, but first, practitioners must overcome ethical challenges en route to medicines for all.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
insitro and Genomics England Announce Partnership to Provide Multimodal Search Capabilities and Empower Data Exploration and Derivation of Novel Insights
3/9/2022
As part of the collaboration, insitro will deploy its machine-learning capabilities on Genomics England’s histopathology images and accompanying genetic data to learn a multimodal representation that captures the fine grained semantic structure in this high-dimensional clinical data.
-
insitro Announces Leadership Team Expansion to Support Advancement of Machine Learning Enabled Drug Discovery and Development Efforts
1/12/2022
insitro, a machine learning-driven drug discovery and development company, today announced the expansion of its leadership team with the appointments of several industry leaders.
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
-
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
-
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand ...
-
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
10/28/2020
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion Collaboration to Advance Targets and Therapeutic Candidates SAN FRANCISCO--( BUSINESS WIRE )-- insitro, a machine-learning driven drug discovery and development compan
-
Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases.
-
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
-
BioSpace Movers & Shakers, Oct. 2
10/2/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
insitro Adds Biopharma Industry Leader Roger Perlmutter as First Independent Board Member
10/1/2020
insitro, a machine-learning driven drug discovery and development company, announced the appointment of Roger Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories, Merck’s global R&D organization, as the company’s first independent board director.
-
The funding will be used to continue to build the company’s technology and automation, which enable data generation at a larger scale. This will expand Insitro’s ability to create predictive models of human disease.
-
BioSpace Movers & Shakers, Dec. 6
12/6/2019
Pharma and biotech companies strengthen their leadership teams and boards with this week's hires. -
insitro Expands Leadership Team with Appointment of Serafim Batzoglou as Chief Data Officer
12/5/2019
Dr. Batzoglou brings to insitro more than two decades of expertise in machine learning and computational genomics as a former Professor of Computer Science at Stanford University and Vice President of Applied and Computational Biology at Illumina.
-
insitro Announces Key Leadership Appointments
9/18/2019
Matthew Rasmussen, Ph.D., Appointed as Vice President, Data Engineering Duane Valz Appointed as General Counsel
-
insitro Strengthens Executive Leadership Team with Key Appointments
8/6/2019
insitro, a machine-learning driven drug discovery and development company, today announced two key leadership appointments.
-
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
4/16/2019
Gilead Sciences Inc. and insitro announced that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis.